Long-term protection provided by hepatitis B vaccine and need for booster dose: A meta-analysis

Vaccine

Volumn 28, Issue 3, 2010, Pages 623-631

  Poorolajal, Jalal ^a   Mahmoodi, Mahmood ^a   Majdzadeh, Reza ^a   Nasseri Moghaddam, Siavosh ^b   Haghdoost, AliAkbar ^c   Fotouhi, Akbar ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Booster; Hepatitis B infection; Hepatitis B vaccine

Indexed keywords

HEPATITIS B VACCINE;

CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNITY; IMMUNOCOMPETENCE; IMMUNOGENICITY; INFECTION RISK; LONG TERM CARE; META ANALYSIS; MORBIDITY; PRIORITY JOURNAL; PUBLISHING; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VACCINATION;

HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; TIME FACTORS;

EID: 71149083898     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.068     Document Type: Review

References (41)

1. Mast E.E., Weinbaum C.M., Fiore A.E., Alter M.J., Bell B.P., Finelli L., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recommendations and Reports 55 RR-16 (2006) 1-33
2. World Health Organization. Hepatitis B. WHO/CDS/CSR/LYO/2002.2;2002:1-76.
3. Dentinger C.M., McMahon B.J., Butler J.C., Dunaway C.E., Zanis C.L., Bulkow L.R., et al. Persistence of antibody to hepatitis B and protection from disease among Alaska Natives immunized at birth. Pediatric Infectious Disease Journal 24 9 (2005) 786-792
4. Wainwright R.B., Bulkow L.R., Parkinson A.J., Zanis C., and McMahon B.J. Protection provided by hepatitis B vaccine in a Yupik Eskimo population-results of a 10-year study. The Journal of Infectious Diseases 175 (1997) 674-677
5. Liao S., Li R., Li H., Yang J., Zeng X., Gong J., et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 17 (1999) 2661-2666
6. McMahon B.J., Bruden D.L., Petersen K.M., Bulkow L.R., Parkinson A.J., Nainan O., et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Annals of Internal Medicine 142 5 (2005) 333-341
7. Banatvala J.E., and Van Damma P. Hepatitis B vaccine-do we need boosters?. Journal of Viral Hepatitis 10 (2003) 1-6
8. Hadler S.C., Francis D.P., Sc D., Maynard J.E., Thompson S.E., Judson F.N., et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. The New England Journal of Medicine 315 4 (1986) 209-214
9. Whittle H., Jaffar S., Wansbrough M., Mendy M., Dumpis U., Collinson A., et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 325 (2002) 569-575
10. European Consensus Group on Hepatitis B Immunity. Are booster immunizations needed for lifelong hepatitis B immunity?. Lancet 355 (2000) 561-565
11. John T.J., and Cooksley G. Hepatitis B vaccine boosters: is there a clinical need in high endemicity populations?. Journal of Gastroenterology and Hepatology 20 (2005) 5-10
12. Puro V., Carli G.D., Cicalini S., Soldani F., Balslev U., Begovac J., et al. European recommendations for the management of healthcare workers occupationally exposed to hepatitis B virus and hepatitis C virus. Euro Surveillance 10 10 (2005) 260-264
13. World Health Organization. Expanded program on immunization: measles and hepatitis B. WHO/WPR/RC54/5;2003:1-60.
14. World Health Organization. Introduction of hepatitis B vaccine into childhood immunization services. WHO/V&B/0131;2001:1-48.
15. Higgins J.P.T., and Green S. Cochrane handbook for systematic reviews of interventions version 5.0.0 [updated February 2008] (2008), The Cochrane Collaboration
16. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.0.0. The Cochrane Collaboration 2008; [cited Feb 2008]. Available from: www.cochrane-handbook.org.
17. RevMan. Review Manager (RevMan) [Computer program]. RevMan. Version 5. 0 for Windows (2008), The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen
18. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 7 (1986) 177-188
19. But D.Y.K., Lai C.L., Lim W.L., Fung J., Wong D.K.H., and Yuen M.F. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 26 (2008) 6587-6591
20. Chadha M.S., and Arankalle V.A. Ten-year serological follow up of hepatitis B vaccine recipients. Indian Journal of Gastroenterology 19 4 (2000) 168-171
21. Durlach R., Laugas S., Freuler C.B., Rodriguez V.E., and Costa M. Ten-year persistence of antibody to hepatitis B surface antigen in healthcare workers vaccinated against hepatitis B virus, and response to booster vaccination. Infection Control and Hospital Epidemiology 24 10 (2003) 773-776
22. Antibody kinetics after vaccination with Engerix-B at the age of 8-10 years and the effect of a booster dose given five or ten years later. In: Gilca V., Serres G.D., Boulianne N., Wals P.D., Trudeau G., Massé R., et al. (Eds). Proceedings of the 8th Canadian Immunization Conference. Toronto, November 30-December 3 (2008)
23. Goh K.T., Oon C.J., Heng B.H., and Lim G.K. Long-term immunogenicity and efficacy of a reduced dose of plasma-based hepatitis B vaccine in young adults. Bulletin of the World Health Organization 73 4 (1995) 523-527
24. Joshi N., Kumar Y.R.N., Srinivas D.V., Kumar A., and Rao P.N. Recombinant hepatitis-B vaccine long-term efficacy in hospital personnel. Gastroenterology 108 4 (1995) A1093
25. Lai C.L., Wong B.C., Yeoh E.K., Lim W.L., Chang W.K., and Lin H.J. Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: immunogenicity and anamnestic responses. Hepatology 18 4 (1993) 763-767
26. Mintai Z., Kezhou L., Lieming D., and Raymond S. Duration and efficacy of immune response to hepatitis-B vaccine in high-risk Chinese adolescents. Clinical Infectious Diseases 16 1 (1993) 165-167
27. Wainwright R.B., McMahon B.J., Bulkow L.R., Hall D.B., Fitzgerald M.A., Harpster A.P., et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 261 16 (1989) 2362-2366
28. Yuen M.F., Lim W.L., Cheng C.C., Lam S.K., and Lai C.L. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology 29 3 (1999) 924-927
29. Zhang M., Liu K., Jin J., Ding L., Zhou S., Yu Q., et al. Five-year follow-up of immune response to hepatitis B vaccine in juveniles. Chinese Medical Journal 106 2 (1993) 97-99
30. Van Herck K., Van Damme P., Thoelen S., and Meheus A. Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results. Vaccine 16 (1998) 1933-1935
31. Xu H., Zuo H., and Zhuang G. Evaluation of the effectiveness nine years after primary immunization with local produced plasma-derived hepatitis B vaccine. Chinese Journal of Preventive Medicine 32 4 (1998) 205-207
32. Long term effectiveness of hepatitis B vaccine in Palau. In: Patel P.R., Armstrong G.L., Samandari T., Talekar S., Yamanguchi K., Kuhnert W.L., et al. (Eds). Proceedings of the 42nd Annual Meeting of IDSA. Boston, September 30-October 3 (2004)
33. Wainwright R.B., Bulkow L.R., Parkinson A.J., Zanis C., and McMahon B.J. Protection provided by hepatitis B vaccine in a Yupik Eskimo population results of a 10-year study. The Journal of Infectious Disease 175 (1997) 674-677
34. Gabbuti A., Romano L., Blanc P., Meacci F., Amendola A., Mele A., et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine 25 (2007) 3129-3132
35. Xu H., Zhuang G., Wang X., Chen Q., and Chen Z. Efficacy and immune memory of plasma-derived hepatitis B vaccine 11 years after primary immunization. Chinese Journal of Preventive Medicine 34 2 (2000) 113-115
36. Liu H.B., Meng Z.D., Ma J.C., Han C.Q., Zhang Y.L., Xing Z.C., et al. A 12-year cohort study on the efficacy of plasma-derived hepatitis B vaccine in rural newborns. World Journal of Gastroenterology 6 3 (2000) 381-383
37. Liao S.-S., Li R.-c., Li H., Yang J.-y., Zeng X.-j., Gong J., et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 17 (1999) 2661-2666
38. Yuen M.F., Lim W.L., Chan A.O., Wong D.K., Sum S.S., and Lai C.L. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clinical Gastroenterology and Hepatology 2 10 (2004) 941-945
39. Alavian S.M., Mansouri S., Abouzari M., Assari S., Bonab M.S., and Miri S.M. Long-term efficacy of hepatitis B vaccination in healthcare workers of Oil Company Hospital, Tehran, Iran (1989-2005). European Journal of Gastroenterology & Hepatology 20 2 (2008) 131-134
40. Egger M., Smith G.D., and Altman D.G. Systematic reviews in health care: meta-analysis in context. 2nd ed. (2001), BMJ Publishing Group, London
41. Agresti A. Statistical inference for a proportion. An introduction to categorical data analysis (2007), John Wiley & Sons, Inc., Hoboken, New Jersey